---
title: "Cardiology"
order: 1
category: "Internal Medicine"
---

# Cardiology

## Overview

Cardiology is the medical specialty dedicated to the diagnosis, treatment, and prevention of diseases affecting the cardiovascular system, including the heart and blood vessels. Cardiovascular disease remains the leading cause of morbidity and mortality worldwide, making cardiology one of the most critical subspecialties in internal medicine.

### Scope of Cardiology
- **Preventive cardiology**: Risk factor modification, lipid management, lifestyle intervention
- **Coronary artery disease**: Acute coronary syndromes, stable angina, revascularization
- **Heart failure**: Systolic and diastolic dysfunction, cardiomyopathies
- **Arrhythmias**: Atrial fibrillation, ventricular arrhythmias, sudden cardiac death
- **Valvular heart disease**: Stenosis and regurgitation, surgical and transcatheter interventions
- **Structural heart disease**: Congenital defects, cardiac tumors, pericardial disease
- **Vascular disease**: Peripheral arterial disease, aortic pathology, venous thromboembolism
- **Interventional cardiology**: Percutaneous coronary intervention, structural interventions

### Epidemiology
- Cardiovascular disease accounts for 31% of global deaths (WHO)
- Coronary artery disease is the single leading cause of death worldwide
- Heart failure affects over 64 million people globally
- Atrial fibrillation prevalence: 2-4% of adults, increasing with age
- Modifiable risk factors account for 90% of myocardial infarction risk

### Major Risk Factors
**Traditional risk factors**:
- Hypertension
- Dyslipidemia (elevated LDL, low HDL)
- Diabetes mellitus
- Tobacco use
- Obesity
- Physical inactivity
- Unhealthy diet
- Family history of premature CAD

**Emerging risk factors**:
- Chronic inflammation (elevated CRP)
- Lipoprotein(a)
- Homocysteine
- Chronic kidney disease
- Obstructive sleep apnea
- Psychosocial stress

## Cardiovascular Anatomy and Physiology

### Cardiac Structure
**Heart chambers**:
- Right atrium: Receives deoxygenated blood from systemic circulation
- Right ventricle: Pumps blood to pulmonary circulation
- Left atrium: Receives oxygenated blood from pulmonary veins
- Left ventricle: Main pumping chamber, supplies systemic circulation

**Cardiac valves**:
- Tricuspid valve: RA to RV
- Pulmonary valve: RV to pulmonary artery
- Mitral valve: LA to LV
- Aortic valve: LV to aorta

**Coronary circulation**:
- Left main coronary artery → LAD and LCx
- LAD supplies anterior LV wall, anterior septum, apex
- LCx supplies lateral and posterior LV wall
- RCA supplies RV, inferior LV wall, posterior septum (in most)

### Cardiac Physiology

**Cardiac cycle**:
- Diastole: Ventricular filling, AV valves open
- Systole: Ventricular contraction, semilunar valves open
- Isovolumetric contraction: All valves closed, pressure rises
- Isovolumetric relaxation: All valves closed, pressure falls

**Hemodynamic parameters**:
- Stroke volume (SV): Volume ejected per beat (~70 mL)
- Cardiac output (CO): SV × HR (~5 L/min at rest)
- Ejection fraction (EF): SV/EDV × 100% (normal 55-70%)
- Cardiac index: CO/body surface area (2.5-4.0 L/min/m²)

**Determinants of cardiac output**:
- Preload: Ventricular end-diastolic volume (Frank-Starling mechanism)
- Afterload: Resistance ventricle must overcome to eject
- Contractility: Intrinsic strength of myocardial contraction
- Heart rate: Rate of ventricular contractions

### Electrical Conduction System
- Sinoatrial (SA) node: Natural pacemaker (60-100 bpm)
- Atrioventricular (AV) node: Delays impulse (0.12-0.20 sec)
- Bundle of His: Transmits impulse to ventricles
- Bundle branches: Right and left divisions
- Purkinje fibers: Distribute impulse throughout ventricles

**Electrocardiogram (ECG)**:
- P wave: Atrial depolarization
- PR interval: AV conduction time (0.12-0.20 sec)
- QRS complex: Ventricular depolarization (<0.12 sec)
- ST segment: Early ventricular repolarization
- T wave: Ventricular repolarization
- QT interval: Total ventricular depolarization and repolarization

## Diagnostic Approaches in Cardiology

### Clinical Assessment

**History**:
- Chest pain characteristics (PQRST: Provocation, Quality, Radiation, Severity, Timing)
- Dyspnea (exertional vs. rest, orthopnea, paroxysmal nocturnal dyspnea)
- Palpitations (rate, rhythm, associated symptoms)
- Syncope or presyncope
- Edema (location, timing)
- Functional capacity (NYHA class, METs)

**Physical examination**:
- Vital signs: BP (both arms), HR, respiratory rate, oxygen saturation
- Jugular venous pressure: Assess right heart pressures
- Cardiac auscultation: Heart sounds, murmurs, gallops, rubs
- Peripheral pulses: Rate, rhythm, character, symmetry
- Peripheral edema: Location, pitting, severity
- Lung examination: Crackles, wheezing, effusions

### Electrocardiography

**Indications**:
- Chest pain or suspected ACS
- Arrhythmia evaluation
- Syncope workup
- Pre-operative assessment
- Monitoring of cardiac medications

**Common ECG findings**:
- ST elevation: STEMI, pericarditis, early repolarization
- ST depression: Ischemia, NSTEMI, digoxin effect, LV strain
- T wave inversion: Ischemia, LVH, PE, CNS events
- Q waves: Prior MI, LVH, LBBB, WPW
- QRS widening: Bundle branch blocks, hyperkalemia, toxins

### Biomarkers

**Cardiac troponin (cTn)**:
- Most sensitive and specific marker for myocardial injury
- Rises 2-4 hours after injury, peaks 12-48 hours
- Remains elevated 7-14 days
- High-sensitivity troponin: Earlier detection of MI

**Natriuretic peptides**:
- BNP and NT-proBNP: Released in response to ventricular stretch
- Diagnostic: Rule out heart failure (high NPV when low)
- Prognostic: Higher levels predict worse outcomes
- Limitations: Affected by age, renal function, obesity

**Other markers**:
- CK-MB: Less specific than troponin, peaks earlier (24 hours)
- D-dimer: Excludes VTE when low, poor specificity
- CRP/hs-CRP: Inflammation, cardiovascular risk assessment

### Echocardiography

**Transthoracic echocardiography (TTE)**:
- First-line imaging for most cardiac conditions
- Assesses chamber sizes, wall thickness, valve function
- Evaluates systolic and diastolic function
- Detects regional wall motion abnormalities
- Estimates pulmonary pressures
- Identifies pericardial effusion

**Transesophageal echocardiography (TEE)**:
- Superior visualization of posterior structures
- Indications: Endocarditis, LA appendage thrombus, aortic dissection
- Intraoperative monitoring during cardiac surgery

**Stress echocardiography**:
- Exercise or pharmacologic stress (dobutamine)
- Detects inducible ischemia (wall motion abnormalities)
- Risk stratification for CAD

### Cardiac Stress Testing

**Exercise ECG**:
- Standard treadmill or bicycle protocol (Bruce protocol)
- Indications: Chest pain evaluation, risk stratification, functional capacity
- Positive test: ST depression ≥1 mm, angina, hypotension, arrhythmias
- Limitations: Cannot interpret if baseline ECG abnormalities (LBBB, LVH, paced)

**Pharmacologic stress**:
- Vasodilators (adenosine, regadenoson): Coronary steal phenomenon
- Inotropes (dobutamine): Increases myocardial oxygen demand
- Used when patient cannot exercise

**Nuclear imaging (SPECT/PET)**:
- Perfusion tracers: Tc-99m sestamibi, thallium-201
- Detects areas of ischemia and infarction
- Higher sensitivity than exercise ECG alone

### Cardiac Catheterization

**Coronary angiography**:
- Gold standard for CAD diagnosis
- Identifies stenosis location and severity
- Guides revascularization decisions
- Indications: ACS, high-risk stress test, heart failure workup

**Hemodynamic assessment**:
- Right heart catheterization: Measures PA pressures, cardiac output, PVR
- Left heart catheterization: LV pressures, gradient assessment
- Indicated in heart failure, valvular disease, pulmonary hypertension

**Fractional flow reserve (FFR)**:
- Physiologic assessment of stenosis significance
- FFR <0.80 indicates hemodynamically significant lesion
- Guides revascularization in intermediate stenoses (40-70%)

### Advanced Imaging

**Cardiac CT**:
- Coronary calcium scoring: Atherosclerosis burden, risk stratification
- CT angiography: Non-invasive coronary assessment, high NPV
- Structural evaluation: Aortic disease, cardiac masses, pericardium

**Cardiac MRI**:
- Gold standard for ventricular volumes and function
- Tissue characterization: Viability, fibrosis, infiltration
- Late gadolinium enhancement: Scar detection
- Stress CMR: Perfusion and wall motion assessment

## Common Cardiovascular Conditions

### Coronary Artery Disease
- Stable angina pectoris
- Acute coronary syndromes (STEMI, NSTEMI, unstable angina)
- Coronary atherosclerosis and risk stratification
- Revascularization strategies (PCI vs. CABG)
- Secondary prevention and medical management

### Heart Failure
- Heart failure with reduced ejection fraction (HFrEF)
- Heart failure with preserved ejection fraction (HFpEF)
- Acute decompensated heart failure
- Advanced heart failure and mechanical support
- Cardiac transplantation

### Cardiac Arrhythmias
- Atrial fibrillation and atrial flutter
- Supraventricular tachycardias (AVNRT, AVRT, atrial tachycardia)
- Ventricular arrhythmias (VT, VF, PVCs)
- Bradyarrhythmias and conduction disorders
- Sudden cardiac death prevention

### Valvular Heart Disease
- Aortic stenosis and regurgitation
- Mitral stenosis and regurgitation
- Tricuspid and pulmonary valve disease
- Prosthetic valve management
- Transcatheter valve interventions (TAVR, MitraClip)

### Cardiomyopathies
- Dilated cardiomyopathy
- Hypertrophic cardiomyopathy
- Restrictive cardiomyopathy
- Arrhythmogenic right ventricular cardiomyopathy
- Stress-induced (Takotsubo) cardiomyopathy

### Pericardial Disease
- Acute pericarditis
- Constrictive pericarditis
- Cardiac tamponade
- Pericardial effusion

### Vascular Disease
- Peripheral arterial disease
- Aortic aneurysms and dissection
- Carotid artery stenosis
- Venous thromboembolism

## Cardiovascular Pharmacology

### Antiplatelet Agents
- **Aspirin**: COX-1 inhibition, reduces TXA2 production
- **P2Y12 inhibitors**: Clopidogrel, prasugrel, ticagrelor
- **Dual antiplatelet therapy (DAPT)**: Post-PCI, ACS management

### Anticoagulants
- **Vitamin K antagonists**: Warfarin (requires INR monitoring)
- **Direct oral anticoagulants (DOACs)**: Apixaban, rivaroxaban, edoxaban, dabigatran
- **Heparins**: Unfractionated heparin, LMWH (enoxaparin)
- **Indications**: Atrial fibrillation, VTE, prosthetic valves

### Lipid-Lowering Therapy
- **Statins**: HMG-CoA reductase inhibitors, first-line for LDL reduction
- **Ezetimibe**: Cholesterol absorption inhibitor
- **PCSK9 inhibitors**: Evolocumab, alirocumab (for high-risk or statin-intolerant)
- **Fibrates**: Gemfibrozil, fenofibrate (for hypertriglyceridemia)

### Antihypertensive Medications
- **ACE inhibitors**: Lisinopril, enalapril (reduce mortality in HFrEF)
- **ARBs**: Losartan, valsartan (alternative to ACE inhibitors)
- **Beta-blockers**: Metoprolol, carvedilol, bisoprolol (post-MI, HFrEF)
- **Calcium channel blockers**: Amlodipine, diltiazem (rate control, angina)
- **Diuretics**: Furosemide, hydrochlorothiazide, spironolactone

### Heart Failure Medications
- **ACE inhibitors/ARBs**: Reduce preload and afterload
- **Beta-blockers**: Reduce mortality, improve remodeling
- **Mineralocorticoid receptor antagonists**: Spironolactone, eplerenone
- **ARNI**: Sacubitril/valsartan (superior to ACE inhibitors in HFrEF)
- **SGLT2 inhibitors**: Dapagliflozin, empagliflozin (reduce HF hospitalization)
- **Diuretics**: Symptom relief, volume management
- **Digoxin**: Symptom improvement, reduces hospitalizations

### Antiarrhythmic Drugs (Vaughan Williams Classification)
- **Class I**: Sodium channel blockers (IA: quinidine; IB: lidocaine; IC: flecainide)
- **Class II**: Beta-blockers (metoprolol, esmolol)
- **Class III**: Potassium channel blockers (amiodarone, sotalol, dofetilide)
- **Class IV**: Calcium channel blockers (diltiazem, verapamil)
- **Other**: Adenosine (SVT termination), digoxin (rate control)

## Interventional Cardiology

### Percutaneous Coronary Intervention (PCI)
**Indications**:
- STEMI: Primary PCI within 90 minutes
- NSTEMI/Unstable angina: Invasive strategy for high-risk patients
- Stable CAD: Refractory angina, high-risk anatomy, large ischemic burden

**Techniques**:
- Balloon angioplasty
- Stent placement (bare-metal vs. drug-eluting)
- Atherectomy (rotational, orbital, directional)
- Thrombectomy

**Complications**:
- Coronary dissection or perforation
- No-reflow phenomenon
- Stent thrombosis
- Contrast-induced nephropathy
- Bleeding and vascular complications

### Structural Heart Interventions

**Transcatheter aortic valve replacement (TAVR)**:
- Treatment for severe symptomatic aortic stenosis
- Alternative to surgical AVR in intermediate to high surgical risk
- Transfemoral, transapical, or transaortic approach

**MitraClip**:
- Percutaneous mitral valve repair
- For severe mitral regurgitation with high surgical risk
- Edge-to-edge repair technique

**Left atrial appendage closure**:
- Device closure (Watchman) for stroke prevention
- Alternative to anticoagulation in atrial fibrillation

**Patent foramen ovale (PFO) closure**:
- Cryptogenic stroke in young patients
- Reduces recurrent stroke risk

## Electrophysiology and Device Therapy

### Cardiac Pacing
**Indications**:
- Symptomatic bradycardia
- AV block (second-degree type II, third-degree)
- Sinus node dysfunction
- After AV node ablation

**Pacemaker types**:
- Single chamber (atrial or ventricular)
- Dual chamber (atrial and ventricular)
- Biventricular (cardiac resynchronization therapy)

### Implantable Cardioverter-Defibrillator (ICD)
**Primary prevention**:
- Ischemic cardiomyopathy with EF ≤35%
- Non-ischemic cardiomyopathy with EF ≤35%
- Hypertrophic cardiomyopathy with high-risk features

**Secondary prevention**:
- Survivors of cardiac arrest
- Sustained ventricular tachycardia

### Cardiac Resynchronization Therapy (CRT)
**Indications**:
- Heart failure with EF ≤35%
- Sinus rhythm with LBBB
- QRS duration ≥150 ms
- NYHA class II-IV on optimal medical therapy

**Benefits**:
- Improves symptoms and quality of life
- Reduces heart failure hospitalizations
- Reduces mortality in selected patients

### Catheter Ablation
**Supraventricular arrhythmias**:
- AVNRT, AVRT (WPW syndrome): Cure rates >95%
- Atrial fibrillation: Pulmonary vein isolation
- Atrial flutter: Cavotricuspid isthmus ablation

**Ventricular arrhythmias**:
- Idiopathic VT (RVOT, fascicular)
- Scar-related VT post-MI
- PVC ablation for cardiomyopathy

## Preventive Cardiology

### Cardiovascular Risk Assessment
**Risk calculators**:
- Pooled Cohort Equations (ACC/AHA)
- SCORE (European)
- Framingham Risk Score
- Reynolds Risk Score

**Risk categories**:
- Low risk: <5% 10-year risk
- Intermediate risk: 5-20% 10-year risk
- High risk: >20% 10-year risk

### Primary Prevention Strategies
**Lifestyle modifications**:
- Mediterranean or DASH diet
- Regular physical activity (150 min/week moderate intensity)
- Weight management (BMI 18.5-24.9 kg/m²)
- Smoking cessation
- Moderate alcohol consumption

**Pharmacologic interventions**:
- Statin therapy: LDL >190 mg/dL, diabetes age 40-75, or 10-year ASCVD risk ≥7.5%
- Aspirin: Consider in select intermediate-risk patients
- Antihypertensive therapy: BP ≥130/80 mmHg with elevated CV risk

### Secondary Prevention
**Post-MI/revascularization**:
- Aspirin + P2Y12 inhibitor (DAPT)
- High-intensity statin (atorvastatin 80 mg, rosuvastatin 40 mg)
- Beta-blocker (at least 1 year post-MI)
- ACE inhibitor or ARB (if EF <40%, HTN, or DM)
- Cardiac rehabilitation

**Target goals**:
- LDL <70 mg/dL (or <55 mg/dL in very high-risk)
- BP <130/80 mmHg
- HbA1c <7% in diabetics
- Smoking cessation
- BMI 18.5-24.9 kg/m²

## Cardiac Emergencies

### Acute Coronary Syndrome Management
**STEMI**:
- Immediate reperfusion: Primary PCI (door-to-balloon <90 min) or fibrinolysis
- Antiplatelet: Aspirin + P2Y12 inhibitor
- Anticoagulation: Heparin or bivalirudin
- Adjunctive: Beta-blocker, ACE inhibitor, statin

**NSTEMI/Unstable angina**:
- Risk stratification: TIMI or GRACE score
- Early invasive strategy (<24 hours) for high-risk features
- Medical management: Antiplatelet, anticoagulation, beta-blocker, statin

### Cardiogenic Shock
**Definition**: Hypoperfusion due to cardiac dysfunction
- SBP <90 mmHg for >30 minutes
- Cardiac index <2.2 L/min/m²
- PCWP >15 mmHg

**Management**:
- Identify and treat underlying cause
- Hemodynamic monitoring
- Inotropic support: Dobutamine, milrinone
- Vasopressor if needed: Norepinephrine
- Mechanical circulatory support: IABP, Impella, ECMO
- Revascularization if ischemic etiology

### Cardiac Tamponade
**Clinical triad (Beck's triad)**:
- Hypotension
- Muffled heart sounds
- Elevated jugular venous pressure

**Echocardiographic findings**:
- Pericardial effusion
- RA and RV diastolic collapse
- Respiratory variation in mitral/tricuspid inflow

**Management**:
- Emergent pericardiocentesis
- Volume resuscitation
- Avoid vasodilators

## Key Points

- Cardiovascular disease is the leading cause of death worldwide, with coronary artery disease being the most common etiology
- Comprehensive cardiovascular assessment includes history, physical exam, ECG, biomarkers, and imaging (echo as first-line)
- Evidence-based therapies significantly reduce mortality in ACS, heart failure, and high-risk patients
- Risk factor modification through lifestyle changes and pharmacotherapy is the cornerstone of prevention
- Interventional and device therapies have revolutionized treatment of structural heart disease and arrhythmias
- Early recognition and treatment of cardiac emergencies is critical for improving outcomes

## References

1. Libby P, Bonow RO, Mann DL, Zipes DP. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 12th ed. Elsevier; 2022.

2. Antman EM, Sabatine MS. Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease. 4th ed. Elsevier; 2013.

3. Kern MJ, Sorajja P, Lim MJ. Cardiac Catheterization Handbook. 7th ed. Elsevier; 2019.

4. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2021;143(5):e72-e227.

5. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. Circulation. 2021;144(22):e368-e454.

6. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032.

7. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140(11):e596-e646.

8. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Circulation. 2013;127(4):e362-e425.

9. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2019;140(2):e125-e151.

10. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143.
